Regarding γ' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity
Blood Cells Mol Dis
.
2024 Mar:105:102825.
doi: 10.1016/j.bcmd.2024.102825.
Epub 2024 Jan 12.
Authors
Lucy Z Kornblith
1
,
Bindhya Sadhanandhan
2
,
Sreepriya Arun
2
,
Rebecca Long
3
,
Alicia J Johnson
4
,
Jamie Noll
5
,
C N Ramchand
6
,
John K Olynyk
3
,
David H Farrell
7
Affiliations
1
Department of Surgery, University of California, San Francisco, CA, USA.
2
Theragen Biologics Pvt Ltd, Chennai, India.
3
Fiona Stanley Fremantle Hospital Group, Murdoch, Western Australia, Australia; Edith Cowan University, Joondalup, Western Australia, Australia.
4
Department of Surgery, Oregon Health & Science University, Portland, OR, USA.
5
Gamma Diagnostics, Portland, OR, USA.
6
MagGenome Pvt Ltd, Chennai, India.
7
Department of Surgery, Oregon Health & Science University, Portland, OR, USA. Electronic address: farrelld@ohsu.edu.
PMID:
38278055
DOI:
10.1016/j.bcmd.2024.102825
No abstract available
Publication types
Letter
Comment
MeSH terms
Biomarkers
Blood Coagulation Tests
COVID-19* / diagnosis
Fibrinogen*
Humans
Risk Factors
Substances
Fibrinogen
Biomarkers